| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 | Jun'17 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Total revenues | ||||||||||
818 | 918 | 936 | 925 | 890 | 1,039 | 943 | 2,128 | 2,464 | 1,205 | 1,428 |
Operating expenses: | ||||||||||
Research and development | ||||||||||
11,055 | 10,598 | 11,761 | 9,481 | 12,490 | 10,928 | 11,950 | 13,686 | 12,224 | 8,067 | 8,201 |
General and administrative | ||||||||||
4,899 | 4,533 | 4,523 | 4,171 | 5,725 | 4,821 | 3,782 | 2,022 | 2,049 | 1,318 | 1,268 |
Total operating expenses | ||||||||||
15,954 | 15,131 | 16,284 | 13,652 | 18,215 | 15,749 | 15,732 | 15,708 | 14,273 | 9,385 | 9,469 |
Loss from operations | ||||||||||
-15,136 | -14,213 | -15,348 | -12,727 | -17,325 | -14,710 | -14,789 | -13,580 | -11,809 | -8,180 | -8,041 |
Other income | ||||||||||
426 | 435 | 558 | 596 | 614 | 617 | 608 | 245 | 137 | 35 | 42 |
Net loss and comprehensive loss | ||||||||||
-14,710 | -13,778 | -14,790 | -12,131 | -16,711 | -14,093 | -14,181 | -13,335 | -11,672 | -8,145 | -7,999 |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | ||||||||||
-0.34 | -0.41 | -0.44 | -0.36 | -0.50 | 1.79 | -0.43 | -1.83 | -2.17 | -1.56 | -1.55 |
Weighted-average number of common shares outstanding, basic and diluted (in shares) | ||||||||||
43,835 | 33,695 | 33,646 | 33,493 | 33,390 | 34,952 | 33,191 | 7,275 | 5,378 | 5,232 | 5,159 |
Collaboration revenue | ||||||||||
Total revenues | ||||||||||
- | - | 936 | 925 | - | 1,038 | 943 | 2,017 | 934 | - | - |
Grant revenue | ||||||||||
Total revenues | ||||||||||
- | - | - | - | - | 0 | 1 | 111 | 1,530 | - | - |